Not enough data
Eva Wesley's articles predominantly focus on the healthcare and pharmaceutical industry, with an emphasis on business transactions and investment activities. Her coverage is heavily reliant on press releases and private sector announcements, indicating a preference for official sources of information.
Given her focus on business transactions within the healthcare industry, Eva may be most receptive to pitches that involve exclusive insights into company strategies, market trends, or expert analysis from reputable figures in the field of healthcare finance or corporate strategy.
Since Eva does not specify a geographic focus but focuses primarily on international companies involved in healthcare investments and transactions, pitches should aim to provide global perspectives rather than being limited to specific regions.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Eva Wesley
Chai Discovery, an OpenAI-backed biotech startup, raised $130 million in Series B funding, reaching a $1.3 billion valuation. Led by General Catalyst and Oak HC/FT, the round brings total funding above $225 million. Chai uses AI models like Chai 2 to accelerate drug discovery, particularly de novo antibody design.
By: Eva Wesley
CAR-T therapies have transformed hematologic cancer care, achieving high remission but facing relapse, toxicity, cost, and slow manufacturing. Innovations include mRNA-based in vivo CAR-T generation for speed and reversibility, dual-target CAR-T to prevent antigen escape, ultra-rapid 48-hour production, and public initiatives optimizing safety, durability, and affordability, expanding applications to solid tumors and autoimmune diseases globally. 0 SHARES
By: Eva Wesley
In 2025, medical research accelerated toward precision and personalized care. Gene editing and gene therapies matured into real treatments, AI transformed diagnosis and drug discovery, and early detection improved for cancer and Alzheimer’s. Advances in HIV prevention and neuroscience signal a structural shift in how diseases are prevented, diagnosed, and treated globally.
By: Eva Wesley
Salmoss Biotech, a Chilean startup, is pioneering regenerative medicine by creating bone implants from salmon-bone waste. Used in 360+ surgeries, the technology is safe, biocompatible, and sustainable. Backed by global partnerships, Salmoss showcases circular economy innovation, positioning Chile and Latin America as leaders in scalable, high-impact medical biotechnology with strong clinical results and sustainability benefits. 0 SHARES
By: Eva Wesley
Haptena Therapeutics, a biotech focused on KRAS-mutated tumors, launched operations and secured €3 million from Claris Ventures. Founded by Chiara Ambrogio and Roberto Chiarle, the company develops precision oncology therapies targeting tumor resistance mechanisms. Funding will advance its lead KRAS G12C program and expand a pipeline for tumors with other oncogenic drivers, aiming to improve long-term patient outcomes. 0 SHARES
In 2025, JAMA highlighted studies shaping medical practice, notably showing GLP-1 drugs cut hospitalization or death in heart failure patients by over 40%, and that shingles vaccination may reduce dementia risk. The selection underscores advances in prevention, therapeutics, and critical evaluation of technologies, revealing unexpected benefits and guiding future healthcare priorities worldwide.
Gilead is acquiring German biotech firm Tubulis for up to $5 billion, benefiting Evotec, which holds a 3.14 percent stake and expects about $100 million upfront plus potential milestone payments. Gilead will pay $3.15 billion initially, with more tied to milestones. The deal strengthens its cancer pipeline and is set to close in 2026.
By: Eva Wesley
A 47-year-old woman with three severe autoimmune diseases received CAR-T cell therapy at a German hospital, achieving one-year remission without further treatment. After years of failed therapies and daily transfusions, modified T cells eliminated harmful B cells, restoring blood counts, reducing clotting risk, and resetting her immune system, dramatically improving health and quality of life.
By: Eva Wesley
Beeline Medicines launches globally with $300M funding and Bristol Myers Squibb assets to develop precision therapies for autoimmune and inflammatory diseases. Led by Saqib Islam, it advances five programs, including lupus drug afimetoran, a TLR7/8 inhibitor in Phase 2. The strategy reflects pharma’s satellite biotech model, aiming for targeted treatments and improved patient outcomes worldwide.
Saxony’s biotech sector seeks more venture capital, faster approvals, and greater AI use to sustain growth. The state continues investing, expanding hubs like Bioz and Biocity, and strengthening networks. With over 300 companies, foreign investments, and cross-industry collaboration, biotech is positioned as a key future sector driven by innovation, technology synergies, and global partnerships.
